S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The Small Biotech Scaring Big Pharma (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The Small Biotech Scaring Big Pharma (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
The Small Biotech Scaring Big Pharma (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The Small Biotech Scaring Big Pharma (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The Small Biotech Scaring Big Pharma (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
The Small Biotech Scaring Big Pharma (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The Small Biotech Scaring Big Pharma (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The Small Biotech Scaring Big Pharma (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
The Small Biotech Scaring Big Pharma (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The Small Biotech Scaring Big Pharma (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The Small Biotech Scaring Big Pharma (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
The Small Biotech Scaring Big Pharma (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
NASDAQ:DYN

Dyne Therapeutics - DYN Stock Forecast, Price & News

$11.00
-0.27 (-2.40%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$10.96
$11.48
50-Day Range
$9.37
$13.19
52-Week Range
$4.30
$15.63
Volume
390,583 shs
Average Volume
219,847 shs
Market Capitalization
$573.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.60

Dyne Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
87.3% Upside
$20.60 Price Target
Short Interest
Bearish
10.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of Dyne Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$2.63 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.35) to ($3.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

781st out of 1,027 stocks

Pharmaceutical Preparations Industry

382nd out of 503 stocks

DYN stock logo

About Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Receive DYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DYN Stock News Headlines

Dyne Therapeutics (NASDAQ:DYN) Trading 6.7% Higher
Dyne Therapeutics: Q3 Earnings Insights
Dyne Gains on FDA Fast-Tracking
Dyne Therapeutics, Inc. (DYN)
DYN Dyne Therapeutics, Inc.
Dyne Therapeutics: Q2 Earnings Insights
Best Momentum Stocks to Buy for July 18th
See More Headlines
Receive DYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DYN Company Calendar

Last Earnings
11/04/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/09/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DYN
Employees
93
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.60
High Stock Price Forecast
$29.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+87.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-149,290,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.15 per share

Miscellaneous

Free Float
30,056,000
Market Cap
$573.40 million
Optionable
Not Optionable
Beta
0.06

Key Executives

  • Mr. Joshua T. BrummMr. Joshua T. Brumm (Age 44)
    CEO, Pres & Director
    Comp: $1.03M
  • Ms. Susanna Gatti High M.B.A.Ms. Susanna Gatti High M.B.A. (Age 54)
    Chief Operating Officer
    Comp: $646.93k
  • Dr. Oxana Beskrovnaya Ph.D. (Age 61)
    Chief Scientific Officer
    Comp: $609.44k
  • Dr. Romesh Subramanian Ph.D. (Age 57)
    Co-Founder & Advisor
  • Mr. Gene Kim (Age 45)
    VP of Fin.
  • Mr. Richard William Scalzo M.B.A.Mr. Richard William Scalzo M.B.A. (Age 36)
    Sr. VP, Head of Fin. & Admin. and Treasurer
  • Ms. Amy Reilly (Age 48)
    Sr. VP and Head of Corp. Communications & Investor Relations
  • Ms. Kate Mitchell
    VP & Head of HR
  • Dr. Thomas-Christian Mix M.D. (Age 55)
    M.S., Sr. VP of Pharmacovigilance
  • Ms. Debra Feldman (Age 52)
    Sr. VP & Head of Regulatory Affairs













DYN Stock - Frequently Asked Questions

Should I buy or sell Dyne Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DYN shares.
View DYN analyst ratings
or view top-rated stocks.

What is Dyne Therapeutics' stock price forecast for 2023?

4 brokerages have issued 1-year target prices for Dyne Therapeutics' shares. Their DYN share price forecasts range from $16.00 to $29.00. On average, they anticipate the company's stock price to reach $20.60 in the next year. This suggests a possible upside of 87.3% from the stock's current price.
View analysts price targets for DYN
or view top-rated stocks among Wall Street analysts.

How have DYN shares performed in 2022?

Dyne Therapeutics' stock was trading at $11.89 at the start of the year. Since then, DYN shares have decreased by 7.5% and is now trading at $11.00.
View the best growth stocks for 2022 here
.

When is Dyne Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our DYN earnings forecast
.

How were Dyne Therapeutics' earnings last quarter?

Dyne Therapeutics, Inc. (NASDAQ:DYN) released its quarterly earnings data on Thursday, November, 3rd. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.15.

When did Dyne Therapeutics IPO?

(DYN) raised $175 million in an initial public offering (IPO) on Thursday, September 17th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel served as the underwriters for the IPO.

What is Dyne Therapeutics' stock symbol?

Dyne Therapeutics trades on the NASDAQ under the ticker symbol "DYN."

Who are Dyne Therapeutics' major shareholders?

Dyne Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (4.84%), Logos Global Management LP (4.39%), Vida Ventures Advisors LLC (4.29%), Point72 Asset Management L.P. (2.87%), Vanguard Group Inc. (2.57%) and State Street Corp (1.11%). Insiders that own company stock include Joshua T Brumm, Richard William Scalzo, Susanna Gatti High and Wildon Farwell.
View institutional ownership trends
.

How do I buy shares of Dyne Therapeutics?

Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dyne Therapeutics' stock price today?

One share of DYN stock can currently be purchased for approximately $11.00.

How much money does Dyne Therapeutics make?

Dyne Therapeutics (NASDAQ:DYN) has a market capitalization of $573.40 million. The company earns $-149,290,000.00 in net income (profit) each year or ($3.50) on an earnings per share basis.

How can I contact Dyne Therapeutics?

The official website for the company is www.dyne-tx.com. The company can be reached via phone at 781-786-8230, via email at ir@dyne-tx.com, or via fax at 781-786-8866.

This page (NASDAQ:DYN) was last updated on 12/8/2022 by MarketBeat.com Staff